- ISIN
- US3847471014
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- IPO Date
- Jun 25, 2024
Highlights
- Market Cap
- $2.52B
- Enterprise Value
- $2.52B
- EPS (TTM)
- -$10.37
- Total Revenue (TTM)
- $156.12M
- Gross Profit (TTM)
- -$23.10M
- EBITDA (TTM)
- -$392.68M
- Year Range
- $29.95 - $118.84
- Target Price
- $77.33
- ROA (TTM)
- -14.10%
- ROE (TTM)
- -15.81%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
GRAL Performance Chart
GRAIL, Inc (GRAL) is down 27.4% since the beginning of the year. At $62 per share, GRAL is trading 47.7% below its 52-week high of $119.
Loading charts...
Returns By Period
GRAIL, Inc (GRAL) has returned -27.44% so far this year and 36.09% over the past 12 months.
GRAIL, Inc
- 1D
- -2.57%
- 1M
- -7.58%
- YTD
- -27.44%
- 6M
- -34.18%
- 1Y
- 36.09%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
GRAL Monthly Returns History
Based on dividend-adjusted daily data since Jun 25, 2024, GRAL's average daily return is +0.47%, while the average monthly return is +9.20%. At this rate, an investment would double in approximately 0.7 years.
Historically, 56% of months were positive and 44% were negative. The best month was Sep 2025 with a return of +80.3%, while the worst month was Feb 2026 at -45.6%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 3 months.
On a daily basis, GRAL closed higher 49% of trading days. The best single day was Feb 13, 2025 with a return of +33.9%, while the worst single day was Feb 20, 2026 at -50.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 14.29% | -45.58% | -2.91% | 5.42% | 31.57% | -13.36% | -27.44% | ||||||
| 2025 | 69.64% | 27.34% | -33.77% | 35.06% | 11.35% | 33.87% | -33.47% | -4.15% | 80.33% | 55.47% | 20.08% | -22.47% | 379.50% |
| 2024 | -17.50% | 0.07% | -8.26% | -2.48% | -1.38% | 28.96% | 2.00% | -4.19% |
Benchmark Metrics
GRAIL, Inc has an annualized alpha of 120.56%, beta of 2.30, and R2 of 0.13 versus S&P 500 Index. Calculated based on daily prices since June 25, 2024.
- This stock captured 828.32% of S&P 500 Index gains and 308.96% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.13 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 120.56%
- Beta
- 2.30
- R²
- 0.13
- Upside Capture
- 828.32%
- Downside Capture
- 308.96%
Return for Risk
Risk / Return Rank
GRAL ranks 57 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for GRAIL, Inc (GRAL) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GRAL | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.67 | ||
| Sortino ratioReturn per unit of downside risk | -1.54 | ||
| Omega ratioGain probability vs. loss probability | 1.17 | 1.37 | -0.19 |
| Calmar ratioReturn relative to maximum drawdown | 0.58 | 2.78 | -2.21 |
| Martin ratioReturn relative to average drawdown | 1.05 | 12.44 | -11.39 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the GRAIL, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the GRAIL, Inc was 62.92%, occurring on Feb 23, 2026. The portfolio has not yet recovered.
The current GRAIL, Inc drawdown is 46.49%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -62.92%Feb 2026 | 1mo 1d | — | 5mo 1dJan 2026 - now |
2025 selloff2025 | -61.12%Apr 2025 | 1mo 19d | 5mo 24d | 7mo 13dFeb 2025 - Sep 2025 |
2024 bear market2024 | -36.58%Oct 2024 | 2mo 17d | 2mo 2d | 4mo 19dJul 2024 - Dec 2024 |
2024 bear market2024 | -27.43%Dec 2024 | 1d | 1mo 5d | 1mo 6dDec 2024 - Jan 2025 |
2024 bear market2024 | -25.39%Jul 2024 | 15d | 6d | 21dJun 2024 - Jul 2024 |
Drawdown Indicators
| GRAL | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -62.92% | -56.78% | -6.14% |
Max Drawdown (1Y)Largest decline over 1 year | -62.92% | -9.10% | -53.82% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -46.49% | -1.80% | -44.69% |
Average DrawdownAverage peak-to-trough decline | -27.67% | -10.71% | -16.96% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 34.39% | 2.03% | +32.36% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of GRAIL, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how GRAIL, Inc is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for GRAL relative to other companies in the Diagnostics & Research industry. Currently, GRAL has a P/S ratio of 15.2. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for GRAL in comparison with other companies in the Diagnostics & Research industry. Currently, GRAL has a P/B value of 1.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with GRAL
Add GRAIL, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with GRAL